


SBI-581

Cat. No.:	HY-139439
Molecular Formula:	C ₂₄ H ₂₁ N ₃ O ₂
Molecular Weight:	383.44
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SBI-581 is an orally active and potent selective serine-threonine kinase TAO3 inhibitor, with an IC ₅₀ of 42 nM. SBI-581 promotes TKS5α accumulation at RAB11-positive vesicles. SBI-581 inhibits invadopodia formation. SBI-581 shows reasonable pharmacokinetics in mice using IP injection. SBI-581 shows antitumor activity ^[1] .
IC₅₀ & Target	IC ₅₀ : 42 nM (TAO3), 237 nM (MEKK3) ^[1]
In Vitro	SBI-581 shows moderate selectivity (> 5-10x) against the majority of a broad panel of kinases ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	SBI-581 (10 mg/kg, IP, once) displays reasonable pharmacokinetics (t _{1/2} =1.5 hr; AUC= 1202 hr*ng/mL; C _{max} = ~2 μM) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Iizuka S, et al. Serine-Threonine Kinase TAO3-Mediated Trafficking of Endosomes Containing the Invadopodia Scaffold TKS5α Promotes Cancer Invasion and Tumor Growth. *Cancer Res.* 2021 Mar 15;81(6):1472-1485.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA